Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride Ion SCHEMBL17601912 | 0.98 | TSHR (0.45) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL29354050 | 0.94 | TSHR (0.42) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL2507036 | 0.94 | TSHR (0.42) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL30943478 | 0.93 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Phosphine SCHEMBL28247442 | 0.93 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL8623356 | 0.93 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL27808614 | 0.93 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL3679296 | 0.92 | TSHR (0.40) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Phosphoric Acid SCHEMBL20981646 | 0.92 | TSHR (0.40) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Phosphoric Acid SCHEMBL5102243 | 0.92 | TSHR (0.40) | TSHRNPSR1RXFP1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055148-A | Conjugates, compositions and methods for treating influenza | 珀杜研究基金会 | 2026-05-15 | — | — | CN | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735440-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-4717702-A2 | CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE | Oxford University Innovation Limited (GB) | 2026-04-01 | — | — | EP | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4291244-B1 | CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE | UNIV OXFORD INNOVATION LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-3999513-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3994134-A1 | PROCESS FOR MANUFACTURING (S)-3-HYDROXY-1-(1H-INDOL-5-YL)-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID 3,5-DIFLUORO-BENZYLAMIDE | Merck Patent GmbH (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994122-A1 | N-FORMYLHYDROXYLAMINES AS NEPRILYSIN (NEP) INHIBITORS, IN PARTICULAR AS MIXED INHIBITORS OF AMINOPEPTIDASE N (APN) AND NEPRILYSIN (NEP) | Pharmaleads (FR) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022078352-A1 | CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3972627-A1 | METHODS FOR PREPARING PSMA CONJUGATES | Endocyte, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3969510-A1 | COMPOSITION AND METHOD FOR THE PREPARATION OF SHEETS, FILMS, FIBERS, AND MOLDED PARTS | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022047008-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3953334-A1 | NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10- {4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)- PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15 -(METHENO)PYRAZOLO [4,3-B] [1,7] DIAZACYCLOTETRADECIN-5(6H)-ONE | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | TSHR 701/4885NPSR1 2154/4885RXFP1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.